Matinas BioPharma Holdings Inc. (MTNB): Price to Sales

Corporate company logo of Matinas BioPharma (MTNB)

Matinas BioPharma is accelerating formula synthesis through robotic metabolism analysis. The company's smoothed P/S ratio visualizes the correlation between price and actual sales, with the metric currently standing at 41.80. Growth potential is based on LNC system patents for B2B licensing, although late-stage trial catalysts are only beginning to emerge, creating a moderate immediate market reaction.

Matinas BioPharma Holdings Inc. - MTNB P/S Multiple (period 07/10/2022 - 05/10/2024)

Metric breakdowns and analytics for Matinas BioPharma (MTNB)

- current price and projected stock value:
Price Chart matinasbiopharma.com|MTNB - Price Target Chart
- stock exchange capitalization data:
Market Value Matinas BioPharma Holdings Inc.|MTNB - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Matinas BioPharma|MTNB - Book Capitalization|Market Capitalization to Book Value matinasbiopharma.com|MTNB - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Matinas BioPharma|MTNB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio matinasbiopharma.com|MTNB - Company Debts|Debt to Book Value Matinas BioPharma Holdings Inc.|MTNB - Company Long-Term Debts|Company Short-Term Debts Matinas BioPharma|Intermediate Liquidity Ratio matinasbiopharma.com
- financial results and valuation multiples details:
MTNB - Net Profit|Company Profit Forecast Matinas BioPharma|MTNB - Price to Earnings Ratio|Price to Future Earnings Ratio matinasbiopharma.com|MTNB - PEG Multiple|EV/EBITDA Multiple Matinas BioPharma Holdings Inc.|MTNB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Matinas BioPharma|MTNB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months matinasbiopharma.com|MTNB - Earnings growth in current year|Net earnings per share growth forecast for next year Matinas BioPharma
- issuer revenue and sales details:
MTNB - Revenue and Sales Volume|Company Future Sales matinasbiopharma.com|MTNB - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Matinas BioPharma Holdings Inc.
Fundamental company analysis:MTNB (Matinas BioPharma Holdings, Inc.)
Core merchandise of Matinas BioPharma Holdings

Since Matinas BioPharma (MTNB) is currently in the clinical trial stage for lipid nanocrystals and has no commercial sales, traditional business valuation based on revenue is difficult. By analyzing the price-to-sales ratio, an investor compares market capitalization with sales volume, which in this case reveals the speculative nature of the valuation and the risk of asset overheating prior to the actual scaling of operations.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Price-to-Revenue Ratio 89bio, Inc. ETNB|AGIO - Market Cap to Revenue|Structure Therapeutics Inc. - P/S Multiple|MDXG - P/S Multiple|RZLT (Rezolute Corp) - Market Cap to Revenue|LXRX: Market Cap to Sales Volume|MBX (MBX Biosciences Inc) - P/S Multiple|altimmune.com (ALT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Aardvark Therapeutics (AARD)|Sagimet Biosciences, Inc. - Market Cap to Revenue Ratio|P/S Multiple BIOA (BioAge Labs Inc.)|P/S Multiple Biomea Fusion Corp BMEA|QNCX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient fractyl.com GUTS|VTVT (vtvtherapeutics.com) - Market Cap to Revenue|Agape ATP - Market Capitalization-to-Revenue Ratio|PLUR (Pluristem Therapeutics) - P/S Multiple|Price-to-Revenue Ratio SYBX|P/S Multiple LPCN|Price-to-Revenue Coefficient sprucebiosciences.com|Price-to-Revenue Ratio Galecto GLTO|Carmell Corp. (CTCX) - Price to Sales|LUMO - Price-to-Revenue Ratio|Price-to-Sales Ratio ONVO|RDUS: P/S Multiple